UNSPSC 51434001: Bepridil

This classification denotes a calcium channel blocker with the molecular formula C24H34N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 755BO701MA, chemically known as 1-pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-n-phenyl-n-(phenylmethyl)- but generally known as bepridil, which bears US NIH Compound Identifier 2351. Bepridil most often comes in base and hydrochloride forms. European Medicines Agency schedules Bepridil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13041MIG.

UNSPSC 51434001 Bepridil is a Commodity code covering specific pharmaceutical active ingredients and formulations procured by state and local health systems, fire departments, and pharmacy benefit programs. State and local governments buy this code when stocking emergency medications, filling prescriptions through state Medicaid or employee health plans, or establishing contracts with manufacturers and wholesalers to supply formulary products. Recent solicitations show purchases of individual medication vials and injections for emergency medical use, as well as broader requests for generic multi-source pharmaceutical supply agreements that encompass this ingredient alongside dozens of other drugs.

Issuing bodies span municipal fire departments, state health agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The City of Tampa's Fire Rescue department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) all sought pharmaceutical supply in the past four months. Recent activity concentrates in Florida, Texas, and Minnesota, though MMCAP's agreement serves Oregon and other participating states as well. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including four specific drug formulations, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the contract term runs one year from award with two optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities, with pricing weighted at 75 percent and contract terms of two years for new vendors. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling future procurement strategy development rather than an immediate competitive award.